Advances in Study on Treatment of Gastrointestinal Stromal Tumor / 胃肠病学

ABSTRACT

Gastrointestinal stromal tumor( GIST)is the most common gastrointestinal mesenchymal neoplasm and accounts approximately 18% of all mesenchymal neoplasms and 1% of all gastrointestinal neoplasms. Morbidity of GIST is about 1-2 per hundred thousand per year. The recurrence rate 5 years after complete resection of malignant GIST is up to 50%,and the median survival of metastatic GIST is only 9 months. Nowadays,endoscopic ultrasonography(EUS)is the first choice management for upper digestive tract GIST with diameter ≤2 cm,however,because of its high degree malignancy,surgical resection is the choice for GIST with diameter > 2 cm,and adjuvant or neoadjuvant chemotherapy with tyrosine kinase inhibitors can be used in case with high risks and difficulties in surgical removal. This article reviewed the advances in study on treatment of GIST.